{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T19:15:55Z","timestamp":1784402155615,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clbc.2020.06.010","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T21:04:05Z","timestamp":1594155845000},"page":"e682-e694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development and Validation of a Nomogram for Individually Predicting Pathologic Complete Remission After Preoperative Chemotherapy in Chinese Breast Cancer: A Population-Based Study"],"prefix":"10.1016","volume":"20","author":[{"given":"Niuniu","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2774-0119","authenticated-orcid":false,"given":"Rui","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2020.06.010_bib1","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2020.06.010_bib2","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/cncr.29348","article-title":"Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States","volume":"121","author":"Mougalian","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2020.06.010_bib3","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.1158\/1078-0432.CCR-13-0916","article-title":"Neoadjuvant therapy as a platform for drug development and approval in breast cancer","volume":"19","author":"Bardia","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2020.06.010_bib4","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1245\/s10434-015-4405-7","article-title":"Landscape of neoadjuvant therapy for breast cancer","volume":"22","author":"Haddad","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2020.06.010_bib5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/sj.bjc.6601616","article-title":"Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients","volume":"90","author":"Ezzat","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2020.06.010_bib6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.6004\/jnccn.2017.0158","article-title":"Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer","volume":"15","author":"Spring","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clbc.2020.06.010_bib7","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/sj.bjc.6602235","article-title":"Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer","volume":"91","author":"Ring","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2020.06.010_bib8","doi-asserted-by":"crossref","first-page":"8331","DOI":"10.1200\/JCO.2005.01.2898","article-title":"Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer","volume":"23","author":"Rouzier","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.010_bib9","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","article-title":"Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors","volume":"24","author":"Guarneri","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.010_bib10","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.010_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2020.06.010_bib12","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1158\/1078-0432.CCR-04-0380","article-title":"Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment","volume":"10","author":"Colleoni","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2020.06.010_bib13","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/annonc\/mdm201","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives, 2006","volume":"18","author":"Kaufmann","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.06.010_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.010_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2020.06.010_bib16","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/1097-0142(20001201)89:11<2145::AID-CNCR1>3.0.CO;2-S","article-title":"Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma","volume":"89","author":"Chang","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2020.06.010_bib17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.bjc.6600749","article-title":"Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome","volume":"88","author":"Faneyte","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2020.06.010_bib18","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.ejca.2010.04.008","article-title":"A\u00a0nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer","volume":"46","author":"Colleoni","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2020.06.010_bib19","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00432-011-0991-3","article-title":"Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy","volume":"137","author":"Keam","year":"2011","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.010_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10549-018-4730-1","article-title":"Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients","volume":"170","author":"Chen","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.06.010_bib21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/bjc.2015.34","article-title":"A\u00a0preoperative nomogram to predict the risk of synchronous distant metastases at diagnosis of primary breast cancer","volume":"112","author":"Boutros","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2020.06.010_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10549-016-4040-4","article-title":"Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis","volume":"161","author":"Jankowski","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.06.010_bib23","doi-asserted-by":"crossref","first-page":"32585","DOI":"10.1038\/srep32585","article-title":"A\u00a0nomogram for predicting the pathological response of axillary lymph node metastasis in breast cancer patients","volume":"6","author":"Jin","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clbc.2020.06.010_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/bjc.2016.444","article-title":"Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy","volume":"116","author":"Fujii","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2020.06.010_bib25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-018-4948-y","article-title":"Only estrogen receptor \u201cpositive\u201d is not enough to predict the prognosis of breast cancer","volume":"172","author":"Ryu","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.06.010_bib26","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred","year":"1998","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2020.06.010_bib27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/sj.bjc.6602950","article-title":"Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma","volume":"94","author":"Jones","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2020.06.010_bib28","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.06.010_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clbc.2013.12.015","article-title":"A\u00a0model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer","volume":"14","author":"Schipper","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2020.06.010_bib30","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1200\/JCO.2012.44.5015","article-title":"Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer","volume":"31","author":"Li","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.010_bib31","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1186\/s12885-019-6485-4","article-title":"Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer","volume":"19","author":"Skarping","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2020.06.010_bib32","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.breast.2015.05.007","article-title":"Mammographic breast density: predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients","volume":"24","author":"Elsamany","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2020.06.010_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12094-019-02112-z","article-title":"Response to immunohistochemical markers\u2019 conversion after neoadjuvant chemotherapy in breast cancer patients: association between imaging and histopathologic analysis","volume":"22","author":"Zhao","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clbc.2020.06.010_bib34","first-page":"1048","article-title":"A\u00a0longitudinal study of the effects of menopause on mammographic features","volume":"11","author":"Boyd","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clbc.2020.06.010_bib35","first-page":"1133","article-title":"Mammographic densities and breast cancer risk","volume":"7","author":"Boyd","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clbc.2020.06.010_bib36","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/jnci\/87.21.1622","article-title":"Mammographic features and breast cancer risk: effects with time, age, and menopause status","volume":"87","author":"Byrne","year":"1995","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2020.06.010_bib37","first-page":"678","article-title":"Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium","volume":"52","author":"Easton","year":"1993","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clbc.2020.06.010_bib38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clbc.2020.06.010_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2020.06.010_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41416-018-0127-5","article-title":"BRCA1\/2 testing: therapeutic implications for breast cancer management","volume":"119","author":"Tung","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2020.06.010_bib41","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","article-title":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial","volume":"3","author":"Hahnen","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2020.06.010_bib42","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djg050","article-title":"Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer","volume":"95","author":"Foulkes","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2020.06.010_bib43","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","article-title":"Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer","volume":"24","author":"Haffty","year":"2006","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820920301543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820920301543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:20:06Z","timestamp":1761513606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820920301543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1526820920301543"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2020.06.010","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and Validation of a Nomogram for Individually Predicting Pathologic Complete Remission After Preoperative Chemotherapy in Chinese Breast Cancer: A Population-Based Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2020.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}